Pubblicazioni dal 1985 al 1991
2000
Boni C., Bisagni G., Savoldi L., Moretti G., Rondini E., Sassi M., Zadro A., De Pas T., Franciosi V., Pazzola A., Vignoli R., Banzi M.C., Pajetta V.
Gemcitabine, Ifosfamide, Cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC)
International Journal of Cancer 87: 724-727, 2000. (IF=4.722)
Di Costanzo F., Canaletti R., Sdrobolini A., Olmeo N., Luppi G., Pucci F., Cavicchi F., Gasperoni S., Rodinò C., Zironi S., Angiona S., Contu A.
Modulation of fluorouracil by methotrexate, leucovorin and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC)
American Journal of Clinical Oncology 23 (3): 314-318, 2000. (IF=2.206)
1999
Franciosi V., Cocconi G., Michiara M., Di Costanzo F., Fosser V., Tonato M., Carlini P., Boni C., Di Sarra S.
Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non small cell lung carcinoma, or malignant melanoma
Cancer 85: 1599-1605, 1999
Cocconi G., Bisagni G., Ceci G., Di Blasio B., De Lisi V., Passalacqua R., Zadro A., Boni C., Morandi P., Savoldi L.:
Three new highly active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma. A randomized phase II trial
Breast Cancer Res. Treat.56: 125-132, 1999. IF=4.696)
Cocconi G., Bella M.A., Lottici R., Leonardi F., Ceci G., Passalacqua R., Di Blasio B., Bordi C., Biscottini B., Melpignano M., De Biasi D., Finardi C., Bacchi M.:
Mature results of a prospective randomized trial comparing two different time schedule of cisplatin in advanced ovarian carcinoma
American Journal of Clinical Oncology 22: 559-567, 1999. (IF=2.206)
Cocconi G., Bisagni G., Bella M., Acito L., Anastasi P., Carpi A., Di Costanzo F., Frassoldati A., Mosconi A., Borrini A., Buzzi P.
Comparison of CMF (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer. A prospective randomized trial.
American Journal of Clinical Oncology 22: 593-600, 1999. (IF=2.206)
1998
Di Costanzo F., Gasperoni S., Malacarne P., Belsanti V., Luppi G., Marzola M., Corgna E., Sdrobolini A., Passalacqua R., Figoli F., Algeri R., Zironi S., Angiona S., Boni C.
High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
American Journal of Clinical Oncology 21 (4): 369-375, 1998.
Boni C., Savoldi L., Bisagni G., Ceci G., Crinò L., De Lisi V., Di Costanzo F., Lasagni L., Manenti AL., Moretti G., Rondini E., Sassi M., Zadro A.
Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC).
European Journal of Cancer 34 (12): 1974-1976, 1998. (IF=4.121)
1997
Passalacqua R., Cocconi G., Caminiti C., Silingardi V., Bella M.A., Bichisao E., Michiara M., Malavasi V., Donati D., Di Costanzo F., Rocca A., Di Sarra S., Scaglione F., Fraschini F.
Double-blind , multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients.
Journal of Clinical Oncology 15: 2467-2473, 1997. (IF=17.793)
1996
De Lisi V., Cocconi G., Angelini F., Cavicchi F., Di Costanzo F., Gilli G., Rodinò C., Soldani M., Tonato M., Finardi C.
The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma.
Cancer 77: 245-250, 1996.
Di Costanzo F., Tagliaventi M., Carlini P., Zironi S., Mazzocchi B., Bella M., Donati D., Acito L., Maggian P., Angiona S.
High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
American Journal of Clinical Oncology 19 (3): 307-310, 1996.
Di Costanzo F., Gasperoni S., Labianca R., Sdrobolini A., Zamparelli G., Angiona S., Bartolucci R., Rossetti R. on behalf of GOIRC and GISCAD.
Preliminary report of an ongoing trial comparing surgery alone versus surgery and chemotherapy in operable gastric cancer.
Journal of Chemotherapy 8 suppl. 4: 104-106, 1996.
1995
Ceci G., Bisagni G., Cocconi G., Rodinò C., Belsanti V., Bertusi M., Buzzi F., Bacchi M.:
Cisplatin and VP16 in metastatic breast carcinoma as a third line chemotherapy. A randomized study comparing low vs high doses of Cisplatin
Tumori 81: 241-244, 1995
Crinò L., Clerici M., Figoli F., Carlini P., Ceci G., Cortesi E., Carpi A., Santini A., Di Costanzo F., Boni C., Meacci M., Corgna E., Darwish S., Scarcella L., Santucci A., Ballatori E., Tonato M.
Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC)
Annals of Oncology 6: 347-353, 1995. (IF=5.647)
Crinò L., Clerici M., Figoli F., Barduagni M., Carlini P., Ceci G., Cortesi E., Carpi A., Santini A., Di Costanzo F. et al.
Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research.
Lung Cancer 12 (suppl 1): S125-132, 1995.
1994
Bisagni G., Cocconi G., Ceci G., De Lisi V., Di Blasio B., Lottici R., Passalacqua R., Finardi C.
M-VAC combination in locally advanced, locally recurrent or metastatic breast carcinoma. A phase II study.
Annals of Oncology, 5: 93-94, 1994. (IF=5.647)
Cocconi G., Bella M., Zironi S., Algeri R., Di Costanzo F., De Lisi V., Luppi G., Mazzocchi B., Rodinò C., Soldani M., Gilli G., Finardi C.
Fluorouracil, Doxorubicin, and Mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A prospective randomized trial of the Italian Oncology Group for Clinical Research.
Journal of Clinical Oncology 12: 2687-2693, 1994. (IF=17.793)
Cocconi G, Bisagni G, Ceci G, Bacchi M:
Aminoglutethimide: the problem of the optimal dose and the indispensability or not of hydrocortisone. In "Clinical use of aromatase inhibitors. Current data and future prospective".
Robustelli Della Cuna, A. Manni, F. Pannuti, EDIMES Ed., Pavia, pp. 97-105, 1994
1992
Cocconi G., Bisagni G., Ceci G., Bacchi M., Boni C., Brugia M., Carpi A., Di Costanzo F., Franciosi V., Gori S., Indelli M., Passalacqua R.
Low-dose aminogluthetimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research
Journal of Clinical Oncology 10:984-989, 1992 (IF=17.793)
Di Costanzo F., Bartolucci R., Calabresi F., Sofra M., Marzola M., Belsanti V., Boni C., Bacchi M.
Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC).
Annals of Oncology, 3:371-376, 1992. (IF=5.647)
Cocconi G., Bella M., Calabresi F., Tonato M., Canaletti R., Boni C., Buzzi F., Ceci G., Corgna E., Costa P., Lottici R., Papadia F., Sofra M., Bacchi M.
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.
New England Journal of Medicine 327: 516-523, 1992. (IF=47.050)
Di Costanzo F.
Best treatment for colorectal cancer and confirmatory trials.
Annals of Oncology 3 (3): 245-246, 1992. (IF=5.647)
1991
Cocconi G., Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G, Colozza MA, De Lisi V, Lottici R, Mosconi AM, Passalacqua R, Tonato M.
Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized study the Italian Oncology Group for Clinical Research
Journal of Clinical Oncology, 9:664-669, 1991 (IF=17.793)
Di Costanzo F., Malacarne P., Zironi S., Marzola M., Corgna E., Figoli F., Bacchi M., Passalacqua R., Algeri R., Bartolucci R.
Preliminary report of high dose of folinic acid and 5-Fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research
Journal of Surgical Oncology, Suppl. 2: 137-140, 1991
1990
Di Costanzo F., Bartolucci R., Sofra M., Calabresi F., Malacarne P., Belsanti V., Boni C., Bacchi M.:
5-fluorouracile vs alte dosi di acido folico e 5-fluorouracile nel carcinoma del colon-retto avanzato. Studio randomizzato del Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Atti “Nuove prospettive in Oncologia – L’associazione Fluorouracile e Folati”, a cura di F. Di Costanzo, Arti Grafiche Nobili Ed. Terni, pp: 71-80, 1990
Cocconi G., Di Costanzo F., Bisagni G., Bacchi M., Buzzi F., Canaletti R., Carpi A., Ceci G., Colozza A., De Lisi V., Lottici R., Passalacqua R., Peracchia G.:
Confronto fra la continuazione della chemioterapia di induzione ed una intensificazione tardiva seguita dalla sospensione di ogni chemioterapia nel carcinoma mammario metastatizzato. Studio randomizzato del Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Proc. “Advances in management of malignancies – 2nd International Congress promoted by Fondazione Internazionale Menarini” a cura di A. Carpi, A. Sagripanti, B. Grassi, Monduzzi Ed. Bologna, pp: 407-419, 1990
Cocconi G., Bisagni G., Bacchi M., Buzzi F., Canaletti R., Carpi A., Ceci G., Colozza A., De Lisi V., Lottici R., Passalacqua R., Peracchia G.
A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (GOIRC)
Annals of Oncology 1: 36-44, 1990 (IF=5.647)
Cocconi G., Lottici R., Bisagni G., Bacchi M., Tonato M., Passalacqua R., Boni C., Belsanti V., Bassi P.
Combination therapy with platinum and etoposide of brain metastases from breast carcinoma
Cancer Investigation, 8: 327-334, 1990
1989
Passalacqua R., Bisagni G., Bertusi M., Donati D., Buzzi F., Di Costanzo F., Basurto C., Gori S.:
Lonidamine in advanced colorectal cancer: a phase II trial of the Italian Oncology Group for Clinical Research (GOIRC)
Tumori 75:277-279, 1989 (IF=0.863)
Roila F., Tonato M., Basurto C., Picciafuoco M., Bracarda S., Donati D., Malacarne P., Monici L., Di Costanzo F., Patoia L., Ballatori E., Tognani G., Del Favero A.:
Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine. A study of the Italian Oncology Group for Clinical Research
Journal of Clinical Oncology 7:1693-1700, 1989 (IF=17.793)
1988
Bacchi M.:
La conduzione di uno studio multicentrico: esperienza GOIRC
in “Sillabo XII Corso di Aggiornamento in Oncologia Medica” a cura dell’AIOM, Gestioni Grafiche Stocchiero Ed., Vicenza; pp 109-128, 1988 (libro)
De Lisi V., Cocconi G., Tonato M., Di Costanzo F., Leonardi F., Soldani M.:
5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a prospective randomized study the Italian Oncology Group for Clinical Research (GOIRC)
Recent Results in Cancer Research, 110:212-218, 1988
1987
Roila F., Tonato M., Basurto C, Bella M., Passalacqua R., MorsiaD., Di Costanzo F., Donati D., Ballatori A., Tognoni G., A. Del Favero:
Antiemetic activity of high doses of metoclopramide combined with metylprednisolone alone in cisplatin treated cancer patients: a randomized double blind trial the Italian Oncology Group for Clinical Research (GOIRC)
Journal of Clinical Oncology. 5: 141-149, 1987 (IF=17.793)
1986
Cocconi G., Tonato M., Di Costanzo F., Bisagni G., Belsanti V., Buzzi F., Ceci G.:
Platinum and Etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (GOIRC)
European Journal of Cancer and Clinical Oncology 22:761-764, 1986 (IF=4.121)
De Lisi V., Cocconi G., Tonato M., Di Costanzo F., Leonardi F., Soldani M.:
Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin and mitomycin (BAFMI) in the treatment of advanced gastric cancer. A phase III trial of the Italian Oncology Group for Clinical Research (GOIRC)
Cancer Treatment Reports 70:481-485, 1986 (IF=5.295)
1985
Tonato M., Roila F., Del Favero A., Tognoni G., Franzosi M.G., Pampallona S. for the Italian Clinical Research Oncology Group (GOIRC):
A pilot study of high dose domperidone as antiemetic in patients treated with cisplatin
European Journal of Cancer 21, 807-810, 1985 (IF=4.121)
Roila F., Tonato M., Basurto C., Ballatori E., Del Favero A., Tognoni G., Franzosi M.G., Passalacqua R. for the Italian Clinical Research Oncology Group (GOIRC):
Antiemetic activity of two different high doses of metoclopramide (MTC) in cisplatin treated cancer patients. A randomized double blind trial
Cancer Treatment Reports. 69, 1353-1357, 1985 (IF=5.295)